Form 4: Fulcrum Therapeutics Director Sonja Banks Granted 36,000 Stock Options

Fulcrum Therapeutics, Inc. Director Sonja Banks was granted 36,000 stock options with an exercise price of $7.38, vesting over one year subject to continued service.

Summary

• Sonja Banks, a Director of Fulcrum Therapeutics, Inc. (FULC), was granted 36,000 stock options.
• The options have an exercise price of $7.38 per share.
• The grant date for these options was June 26, 2025.
• The options are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.
• Vesting is contingent upon continued service to the company.
• The expiration date for these stock options is June 25, 2035.

Sentiment

Score: 6

Explanation: The filing reports a standard compensation event (stock option grant) for a director, which is generally a neutral to slightly positive signal as it aligns interests, but does not contain significant new financial or operational information.

Positives

• The grant of stock options aligns the interests of Director Sonja Banks with those of shareholders, incentivizing long-term company performance.
• Stock options are a common and effective tool for attracting and retaining qualified board members in the biotechnology sector.

Negatives

• The issuance of new stock options represents potential future dilution for existing shareholders if the options are exercised.

Risks

• The vesting of the stock options is subject to Sonja Banks' continued service to Fulcrum Therapeutics, Inc.

Future Outlook

The stock options are scheduled to vest fully on the first anniversary of the grant date or earlier, immediately prior to the first annual meeting of stockholders after the grant date, contingent on continued service.

Industry Context

The granting of stock options to directors is a standard practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages to align leadership incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of 36,000 stock options to a director with a 1-year cliff vesting and a 10-year expiration is a common structure for director compensation in the biotech industry, comparable to practices seen at similar-stage biopharmaceutical companies. Specific comparable companies or projects are not detailed in the filing.

Related Party Transactions

• The grant of stock options to a director constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors. This is a standard form of compensation.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also improved alignment of director's interests with long-term shareholder value.

Next Steps

• The stock options will vest on the first anniversary of the grant date (June 26, 2026) or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

Key Dates

Keywords

Fulcrum Therapeutics, FULC, Sonja Banks, stock options, director compensation, insider transaction, Form 4, equity grant, beneficial ownership, biotech, pharmaceutical